A New Era of Clinical Dopamine Transporter Imaging Using 123I-FP-CIT

Journal of Nuclear Medicine Technology

Eunkyung Park¹ 

[1] Department of Nuclear Medicine, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York Department of Nuclear Medicine, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York Department of Nuclear Medicine, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York

关键词: dopamine transporter;    Parkinson disease;    FP-CIT;    ioflupane;    DaTSCAN;   

DOI  :  10.2967/jnmt.112.111617

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

123I-labeled 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane (123I-FP-CIT) was approved for clinical use in 2011 by the Food and Drug Administration. 123I-FP-CIT is a radioligand for brain dopamine transporter (DAT) imaging that is useful for the differential diagnosis of Parkinson disease (PD) and other diseases that mimic PD. The sensitivity and specificity of 123I-FP-CIT SPECT for PD diagnosis are more than 90% and equivalent to those of other DAT SPECT methods. In the near future, the clinical indications of DAT imaging are expected to be broadened; for example, including treatment response assessment, disease progression monitoring, and early diagnosis of premotor PD in each individual patient.

【 授权许可】

Unknown